PMHC cellular microarray

Biocytogen Officially Launches RenMice® Series

Retrieved on: 
Friday, September 15, 2023
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Monoclonal antibody, Antigen, Immunization, Human, Drug development, Therapy, Phla–Pherá languages, PMHC cellular microarray, TIL, HLA, G protein-coupled receptor, CMC, Immune tolerance, MHC, NK, Multimedia, Toxicity, Antibody, Medication, TCR, Knob, Service provider, TILS, HKEX, CTAS, Collection, KIH, Risk, Drug discovery, Epitope, Mouse, Mutagenesis, Spacecraft, Hook effect, Virus, CDR3, Safety, Vaccine

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) officially announces the RenMice® series, which includes a collection of independently developed, fully human antibody mice and TCR mice with proprietary intellectual property.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) officially announces the RenMice® series, which includes a collection of independently developed, fully human antibody mice and TCR mice with proprietary intellectual property.
  • The RenMice® series encompasses five strains of fully human antibody/TCR mice: RenMab™, RenLite®, RenNano®, RenTCR™, and RenTCR-mimic™.
  • View the full release here: https://www.businesswire.com/news/home/20230915794363/en/
    RenMice Series and Their Drug Discovery Applications (Graphic: Business Wire)
    Since their successive release in 2019, Biocytogen’s RenMice series has received global recognition in the biopharmaceutical and biotechnology field.
  • As of June 30, 2023, Biocytogen has entered into RenMice licensing agreements with 20 biopharmaceutical/biotechnology companies worldwide; 42 target-nominated antibody development projects have been initiated.

Biocytogen Officially Launches RenMice® Series

Retrieved on: 
Friday, September 15, 2023
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Monoclonal antibody, Antigen, Immunization, Human, Drug development, Therapy, Phla–Pherá languages, PMHC cellular microarray, TIL, HLA, G protein-coupled receptor, CMC, Immune tolerance, MHC, NK, Multimedia, Toxicity, Antibody, Medication, TCR, Knob, Service provider, TILS, HKEX, CTAS, Collection, KIH, Risk, Drug discovery, Epitope, Mouse, Mutagenesis, Spacecraft, Hook effect, Virus, CDR3, Safety, Vaccine

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) officially announces the RenMice® series, which includes a collection of independently developed, fully human antibody mice and TCR mice with proprietary intellectual property.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) officially announces the RenMice® series, which includes a collection of independently developed, fully human antibody mice and TCR mice with proprietary intellectual property.
  • The RenMice® series encompasses five strains of fully human antibody/TCR mice: RenMab™, RenLite®, RenNano®, RenTCR™, and RenTCR-mimic™.
  • View the full release here: https://www.businesswire.com/news/home/20230914583107/en/
    RenMice Series and Their Drug Discovery Applications (Graphic: Business Wire)
    Since their successive release in 2019, Biocytogen’s RenMice series has received global recognition in the biopharmaceutical and biotechnology field.
  • As of June 30, 2023, Biocytogen has entered into RenMice licensing agreements with 20 biopharmaceutical/biotechnology companies worldwide; 42 target-nominated antibody development projects have been initiated.

Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class of Antibody Therapies That Mimic T-Cell Receptors to Treat Cancer

Retrieved on: 
Tuesday, July 11, 2023
BioImpacts, Biotechnology, Antibody, AstraZeneca, TCR, Novartis, Cancer, Sanofi, Eli Lilly and Company, Entrepreneurship, Therapy, MPM, Corporate development, Pharmaceutical industry, Crossbow, Polaris Partners, Merck, PMHC cellular microarray, Pfizer

CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, today announced an $80 million Series A funding round led by MPM BioImpact and Pfizer Ventures, with participation from Polaris Partners, BVF Partners, Eli Lilly and Company, Mirae Asset Venture Investment, and Mirae Asset Capital.

Key Points: 
  • The Series A financing will allow Crossbow to advance the development of novel therapies that potently target peptide-loaded major histocompatibility complexes (pMHCs) on cancer cells, using antibodies that mimic T-cell receptors (TCR-mimetics).
  • Using proprietary technology, the company then develops TCR-mimetic antibodies with both high affinity and specificity for cancer cells.
  • “With unparalleled accuracy and potency, our revolutionary T-Bolt™ products strike cancer cells like a crossbow shoots bolts at its target.
  • Dmitri Wiederschain, Ph.D., recently joined the company as Chief Scientific Officer after previous leadership roles at Jounce Therapeutics, Sanofi, and Novartis.

AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023

Retrieved on: 
Monday, April 17, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Translation, Bispecific monoclonal antibody, Orange County Convention Center, AACR, Senior, ABCL, TCE, Antibody, Patient, Translational research, Trichloroethylene, Poster, Society, Vaccine, Dry cleaning, Partnering, AbCellera, PMHC cellular microarray

AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) platform in two poster presentations at the American Society for Cancer Research (AACR) Annual Meeting 2023, which is being held at the Orange County Convention Center in Orlando, Florida, from April 14 to 19, 2023.

Key Points: 
  • AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) platform in two poster presentations at the American Society for Cancer Research (AACR) Annual Meeting 2023, which is being held at the Orange County Convention Center in Orlando, Florida, from April 14 to 19, 2023.
  • AbCellera debuted its TCE platform at AACR 2022 with data describing the diversity of its CD3-binding antibodies.
  • Presentations at AACR 2023 illustrated how AbCellera streamlines the development of TCEs with optimal functional properties for diverse tumor targets.
  • The presentation included:
    A comprehensive data package on a panel of CD3-binding antibodies, including binding and functional comparisons to molecules commonly used for TCE development.

Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023

Retrieved on: 
Wednesday, March 22, 2023
Research, Hospitals, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, DNA, Circulating tumor DNA, AACR, PMHC cellular microarray, TMB, ICI, SIM, HLA, IO, University Medical Center, OS, Cancer, American Association for Cancer Research, ICB, NSCLC, Biomarker, Meta-analysis, Immunotherapy, PPV, PSNL, Whole genome sequencing, MRD, Plasma, University Medical Center Hamburg-Eppendorf, Portrait, UKE, Patient, Melanoma, SIB, Immune system, TME, DdPCR, Neoplasm, LUAD, Medical imaging, Chief Justice of Hungary

Personalis, Inc. (Nasdaq: PSNL) today announced it is presenting new research data as scientific posters at the American Association for Cancer Research (AACR) Annual Meeting 2023, which convenes from April 14-19, 2023 in Orlando, Florida.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL) today announced it is presenting new research data as scientific posters at the American Association for Cancer Research (AACR) Annual Meeting 2023, which convenes from April 14-19, 2023 in Orlando, Florida.
  • Most ctDNA-based MRD detection methods leverage a limited genomic footprint, restricting detection sensitivity and thus their utility in many clinical settings.
  • Along with proprietary algorithms, this achieves high MRD sensitivity with a limit of detection of 1 ~ 3 parts per million.
  • Relapses in early-stage LUAD patients were associated with neoantigens with lower immunogenicity and an immunosuppressive tumor microenvironment (TME).

AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023

Retrieved on: 
Tuesday, March 14, 2023
Biotechnology, Pharmaceutical, Health, American Association for Cancer Research, PMHC cellular microarray, AACR, Orange County Convention Center, Antibody, ABCL, Vaccine, AbCellera

AbCellera will present the complete characterization of its panel of differentiated CD3-binding antibodies and demonstrate how it enables customized design of T-cell engagers for cancer targets.

Key Points: 
  • AbCellera will present the complete characterization of its panel of differentiated CD3-binding antibodies and demonstrate how it enables customized design of T-cell engagers for cancer targets.
  • Additionally, AbCellera will present data on the discovery and characterization of antibodies against MAGE-A4, a validated peptide-MHC (pMHC) target for cancer treatment.
  • Together, these two presentations illustrate how AbCellera’s CD3 panel integrates with its antibody discovery and development engine to streamline T-cell engager development.
  • Details on AbCellera’s poster presentations at AACR are as follows:
    Date and Time: Monday, April 17 from 9:00 a.m. to 12:30 p.m.

Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
Hall, Regulatory T cell, Immunotherapy, Research, Department, Population, MOS, Securities Exchange Act of 1934, Policy, Company, Bag valve mask, Standard of care, Drug Quality and Security Act, HPV16, Recurrence, CUE, Forward-looking statement, Molecule, Patent, Food, DSD, Board, Society for Immunotherapy of Cancer, Securities Act of 1933, Board of directors, Cancer, Science, Patient, Analysis, Result, PBMC, Selective, COVID-19, Risk, Conversation, Form 10-Q, Nasdaq, EST, HNSCC, HIV disease progression rates, SITC, Food and Drug Administration, Toxicity, Clinical trial, Poster, Society, FDA, GLOBE, Head, H. Lee Moffitt Cancer Center & Research Institute, Financial condition report, PMHC cellular microarray, HPV, CD8, CPS, Annual report, Pembrolizumab, CBR, ORR, SOC, Pharmaceutical industry, Cassette tape, Vaccine, Animal

The data will be presented in a poster at the Society for Immunotherapy of Cancers 37th Annual Meeting ( SITC 2022 ), to be held in Boston, Massachusetts and virtually on November 8-12, 2022.

Key Points: 
  • The data will be presented in a poster at the Society for Immunotherapy of Cancers 37th Annual Meeting ( SITC 2022 ), to be held in Boston, Massachusetts and virtually on November 8-12, 2022.
  • At the CUE-101 2 mg/kg dose plus pembrolizumab (n=3), one patient experienced a cPR and one DSD, for a CBR of 67%.
  • At the CUE-101 1 mg/kg dose plus pembrolizumab (n=3), one patient experienced DSD, for a CBR of 33%.
  • We look forward to continuing to evaluate data from the trial in addition to defining the potential registrational trial for CUE-101, which we anticipate in mid-2023.

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
Pembrolizumab, Regulatory T cell, Drug Quality and Security Act, Head, Science, SITC, Policy, Annual report, Securities Exchange Act of 1934, Patient, H. Lee Moffitt Cancer Center & Research Institute, Result, Research, Financial condition report, Immunotherapy, Nasdaq, Securities Act of 1933, Cancer, Conversation, Society for Immunotherapy of Cancer, Food, PMHC cellular microarray, Hall, Food and Drug Administration, Department, Analysis, Society, Board, HPV16, Patent, Selective, GLOBE, EST, IL-2, Board of directors, Forward-looking statement, FDA, COVID-19, Form 10-Q, Risk, Pharmaceutical industry, Vaccine, Animal

EST

Key Points: 
  • EST
    Date: Friday, November 11, 2022, Poster Hall (Hall C) 9 a.m.8:30 p.m. EST
    Date: Thursday, November 10, 2022, Poster Hall (Hall C) 9a.m.9p.m.
  • EST
    All posters will be available to conference attendees as virtual e-posters during SITC 2022.
  • The posters will also be available on November 10, 2022 in the Investor & Media section of the Companys website at www.cuebiopharma.com , underScientific Publicationsand Presentations.
  • The CUE-100 series consists of Fc-fusion biologics that incorporate peptide-MHC (pMHC) molecules along with rationally engineered IL-2 molecules.

Cue Biopharma to Present at Two September 2022 Scientific Conferences

Retrieved on: 
Wednesday, September 7, 2022
Cue, COVID-19, Cancer, Securities Exchange Act of 1934, Convention center, Autoimmune disease, Research, Papilloma, Securities Act of 1933, Risk, Result, WT1, Board, PMHC cellular microarray, Drug Quality and Security Act, Policy, Food, Conversation, Patent, Pembrolizumab, Form 10-Q, GLOBE, Board of directors, Nasdaq, FDA, Selective, Financial condition report, APC, Annual report, Analysis, Forward-looking statement, TCR, Patient, Pharmaceutical industry, Vaccine

Dr. Quayle will discuss preclinical data supporting CUE-401s mechanism of action and potential opportunity for the treatment of patients with autoimmune and graft-versus-host disease.

Key Points: 
  • Dr. Quayle will discuss preclinical data supporting CUE-401s mechanism of action and potential opportunity for the treatment of patients with autoimmune and graft-versus-host disease.
  • Cue Biopharma plans to advance the CUE-400 series programs through strategic partnerships.
  • This design enables Immuno-STAT biologics to engage with the T cell population of interest, resulting in selective T cell modulation.
  • Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patients body to transform the treatment of cancer.

Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - expressing cancers

Retrieved on: 
Monday, August 22, 2022
HLA, COVID-19, Breast, Glioblastoma, Lymphatic system, Safety, Securities Exchange Act of 1934, Cancer, Securities Act of 1933, Autoimmune disease, Research, Regulatory T cell, Time, Immunoglobulin G, Risk, AML, Toxic shock syndrome toxin, Result, WT1, Board, PMHC cellular microarray, Drug Quality and Security Act, Policy, Food, Conversation, Lung, Patent, Form 10-Q, GLOBE, Patient, FC, Board of directors, Nasdaq, FDA, Selective, Financial condition report, APC, Annual report, Analysis, Forward-looking statement, Trial of the century, TCR, Pharmaceutical industry, Vaccine

The study will initially focus on colorectal, gastric, pancreatic, and ovarian cancers.

Key Points: 
  • The study will initially focus on colorectal, gastric, pancreatic, and ovarian cancers.
  • Patients with WT1-expressing cancers, and those with recurrent metastatic disease, represent an important unmet clinical need and underscore the opportunity for this promising new therapeutic.
  • WT1 is a well-recognized onco-fetal protein known to be over-expressed in several cancers, including solid tumors and hematologic malignancies.
  • This design enables Immuno-STAT biologics to engage with the T cell population of interest, resulting in selective T cell modulation.